Akari Therapeutics (AKTX) Non-Current Deferred Tax Liability (2024 - 2026)

Akari Therapeutics has disclosed Non-Current Deferred Tax Liability across 3 years of filings, most recently posting $6.1 million for Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $6.1 million, down 24.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.1 million (down 24.2% YoY), and the FY2025 annual result was $7.0 million, down 13.53% from the prior year.
• Non-Current Deferred Tax Liability came in at $6.1 million for Q1 2026 at Akari Therapeutics, down from $7.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $8.0 million in Q4 2024 to a low of $6.1 million in Q1 2026.
• The 3-year median for Non-Current Deferred Tax Liability is $7.5 million (2024), against an average of $7.4 million.
• Across the five-year window, Non-Current Deferred Tax Liability declined 13.53% in 2025 and dropped 24.2% in 2026, its largest moves.
• Akari Therapeutics' Non-Current Deferred Tax Liability stood at $8.0 million in 2024, then retreated by 13.53% to $7.0 million in 2025, then fell by 12.34% to $6.1 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $6.1 million (Q1 2026), $7.0 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.